Investment analysts at StockNews.com began coverage on shares of Jaguar Health (NASDAQ:JAGX – Get Free Report) in a report issued on Monday. The firm set a “sell” rating on the biotechnology company’s stock.
Jaguar Health Stock Performance
JAGX opened at $0.32 on Monday. The company has a 50-day moving average of $0.32 and a 200-day moving average of $0.50. Jaguar Health has a 1-year low of $0.21 and a 1-year high of $11.99. The company has a debt-to-equity ratio of 2.89, a current ratio of 0.97 and a quick ratio of 0.69.
Jaguar Health (NASDAQ:JAGX – Get Free Report) last released its earnings results on Monday, August 14th. The biotechnology company reported ($0.42) EPS for the quarter. Jaguar Health had a negative return on equity of 1,146.88% and a negative net margin of 402.00%. The business had revenue of $2.68 million during the quarter. As a group, analysts forecast that Jaguar Health will post -5.83 EPS for the current year.
Institutional Investors Weigh In On Jaguar Health
Jaguar Health Company Profile
Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
- Five stocks we like better than Jaguar Health
- Roth IRA Calculator: Calculate Your Potential Returns
- MarketBeat Week in Review – 10/30 – 11/3
- How to Read Stock Charts for Beginners
- Shocking uranium play that hedge funds kept hidden
- Video Game Stocks: How to Invest in Gaming
- Dependable dividends: Why utility stocks are on fire
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.